Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    Hyderabad – A groundbreaking study by the Indian Council of Medical Research’s National Institute of Nutrition (ICMR-NIN) has established a clear association between micronutrient deficiencies and elevated dementia risk among Indian…

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    Chatra: The Chatra administration on Sunday sealed a private nursing home operating near Chatra bus stand following the death of a 20-year-old pregnant woman and her unborn child. The deceased…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

    Drug companies directed to step up vigil on adverse reactions

    Drug companies directed to step up vigil on adverse reactions

    Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities

    Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities